SureTrader SPDR Advertisement
Home > Boards > US OTC > Medical - Drugs >

AVAX TECHNOLOGIES INC (AVXT)

AVXT RSS Feed
Add AVXT Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator marketraider, johnny canuck, Rookiemove
Search This Board:
Last Post: 8/31/2015 3:29:29 PM - Followers: 34 - Board type: Free - Posts Today: 0

 

Industry Center - Biotechnology

Contact Information
Address: 2000 Hamilton St., Ste. 204
Philadelphia, PA 19130
Phone: 215-241-9760
Fax: 215-241-9684
Key People
Chairman and CEO: John K. A. Prendergast
CFO and Director: Richard P. (Rich) Rainey
 
 
AVAX Technologies wants to turn cancer cells into cancer fighters. The company is developing vaccines created by extracting a patient's own cancer cells and chemically treating them to induce an immune system response. The technology used to create the vaccines (called AC Vaccine) is licensed from Thomas Jefferson University. AVAX's lead vaccine candidate MVax is intended as a treatment for late-stage melanoma. The company is also developing vaccine candidates to fight ailments such as ovarian cancer (OVax) and non-small cell lung cancer (LungVax).
Business Summary  

AVAX Technologies, Inc., a development stage biotechnology company, together with its subsidiaries, engages in the development and future commercialization of individualized vaccine therapies and other technologies for the treatment of cancer in the United States and Europe. The company's autologous cell vaccine candidates include M-Vax under Phase III clinical status, which is used for the treatment of melanoma; L-Vax under Phase I-II clinical status that is used for the treatment of non-small cell lung cancer; and O-Vax under Phase I-II clinical status, which is used for the treatment of ovarian cancer. It also offers biological manufacturing services to other biotechnology and pharmaceutical companies; and contract manufacturing services in for cell and gene therapy, and biological products in France. AVAX Technologies, Inc. was founded in 1990 and is based in Philadelphia, Pennsylvania.

 


AVAX Technologies, Inc. Files Form 10 With SEC

Press Release Source: AVAX Technologies, Inc. On Friday February 4, 2011, 12:41 pm EST

PHILADELPHIA, Feb. 4, 2011 /PRNewswire/ -- AVAX Technologies, Inc. (Pink Sheets:AVXT.pk - News) ("AVAX" or the "Company") today announced that it filed a Form 10 with the Securities and Exchange Commission ("SEC").  Upon the effectiveness of this Form 10, AVAX will once again become a publicly reporting company.  The Company intends to seek to have its common stock trade on the Over-the-Counter Bulletin Board.

The Company's Form 10, which contains among other things, recent information about the Company's business, operations, financial results and capitalization, can be accessed through the website maintained by the SEC at www.sec.gov.

About AVAX Technologies, Inc.

AVAX Technologies, Inc. is a biotechnology company headquartered in Philadelphia, PA.   The Company is engaged in the research and clinical and commercial development of biological products and cancer therapeutics.

The Company's AC Vaccine platform is a therapeutic cancer vaccine.

Forward-Looking Statements

Certain statements in this release are "forward-looking" statements.   Forward-looking statements involve significant risks and uncertainties, and in light of the significant uncertainties inherent in such statements, the inclusion of such information should not be regarded as a representation by the Company that the objectives and plans of the Company will be achieved. In fact, actual results could differ materially from those contemplated by such forward-looking statements. These statements include, but are not limited to, the Company's immediate need to obtain additional funding to continue to finance the Company, the Company's plans, objectives, projections, expectations and intentions such as those relating to the future development of M-VAX® and its other vaccine candidates, as well as other important factors discussed in the Company's Form 10.   The Company does not undertake any obligation to release publicly any revisions to these forward-looking statements or to reflect the occurrence of unanticipated events. 


Press Releases & AVAX Information:

https://en.wikipedia.org/wiki/Avax_Technologies

2/4/2001: AVAX Technologies, Inc. Files Form 10 With SEC


http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551891/

http://www.ncbi.nlm.nih.gov/pubmed/22854662

http://www.clinicaltrials.gov/ct2/show/NCT00477906?term=MVax&rank=1

http://clinicaltrials.gov/show/NCT00660101

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PG01&s1=20130309271&OS=20130309271&RS=20130309271

http://www.biotechblog.org/Tags/cancer-treatment-centers-of-america/

http://www.thefreelibrary.com/AVAX+Technologies+Announces+Collaboration+with+Cancer+Treatment...-a0159564876

http://www.reuters.com/article/2014/01/08/ctca-trial-cancer-idUSnPnDChVKwJ+16d+PRN20140108

http://ih.advfn.com/p.php?pid=nmona&article=61013370

http://www.bizjournals.com/philadelphia/blog/health-care/2014/02/ovarian-cancer-vaccine-testing-expands.html

http://www.avax-tech.com/about/pdfs/avaxfactsheet.pdf

AVAX Announces Settlement Agreement with Cancer Treatment Centers of America and Approves $45 Million Private Placement Financing

 
By

Published: Aug 4, 2015 7:31 p.m. ET

Share
 
 
 
 

PHILADELPHIA, Aug 04, 2015 (BUSINESS WIRE) -- AVAX Technologies, Inc., (“AVAX” or “The Company”) (AVXT – OTCMKTS), a leading developer of proprietary cancer immunotherapy products, has signed a Settlement & Release Agreement with Cancer Treatment Centers of America Inc. (“CTCA”) to positively resolve the existing debt obligations owed to CTCA.

Under the terms of the Settlement Agreement, CTCA has agreed to settle its $5,826,464.73 Judgment against AVAX in exchange for 860,000 Series A Convertible Preferred Shares at a consideration of $5.00 per share, and a one-time payment of $1.5 million in cash. Firebird Management, a shareholder and a creditor of AVAX, has agreed to swap its outstanding debt for the Series A Convertible Preferred Shares also at a consideration of $5.00 per share.

Andrew Dahl, AVAX Board Member noted, “we are extremely happy to be able to move forward with the reorganization of AVAX’s balance sheet and look forward to re-commencing the important planned clinical trials at AVAX. Our previous work with CTCA on clinical programs has been very successful.”

Richard Rainey, Acting Chief Executive Officer of AVAX, stated, “We are pleased that throughout the development of our AC Vaccine® platform, all of our data has remained consistently positive and has supported further development of the treatment. We feel our immunotherapy platform is consistent with recently approved products and could be additive to the benefits achieved in helping patients with cancer.”

SGC Canada Inc., is acting on behalf of AVAX with its creditors in negotiating its informal restructuring plan. David Holden, the Senior Corporate Advisor of SGC states that “AVAX will be effectively debt-free once the Financial Restructuring & Refinancing Plan is completed.” The Board of AVAX has previously approved the engagement of Phoenix Corporate Finance Inc., a corporate finance firm which specializes in alternative financing, to advise, structure, and facilitate the distribution of a proposed Private Placement financing. through select securities dealers in the US and Canada. AVAX intends to raise $45 million to fund its next round of clinical testing through the issuance of the Series A Convertible Preferred Shares.


AVAX TECHNOLOGIES WEBSITE IS NOW ACTIVE:    WWW.AVAX-TECH.COM/


 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AVXT
Current Price
Volume:
Bid Ask Day's Range
Wiki
PostSubject
#908  Sticky Note HUGE!!! ON AVAX-TECH WEBSITE!! New Rookiemove 08/31/15 10:55:42 AM
#768  Sticky Note AVAX Announces Settlement Agreement with Cancer Treatment Centers marketraider 08/10/15 08:21:47 PM
#909   Nice, check out that bid!! GO AVXT !! Rookiemove 08/31/15 03:29:29 PM
#908   HUGE!!! ON AVAX-TECH WEBSITE!! New Rookiemove 08/31/15 10:55:42 AM
#907   I believe more eyes are on AVXT than Rookiemove 08/29/15 09:26:01 PM
#906   Agreed, heavy loading for two weeks by big money. Rookiemove 08/28/15 05:20:28 PM
#905   No one whacked the rest of the .014s Rookiemove 08/28/15 04:14:11 PM
#904   Nice volume today johnny canuck 08/28/15 04:09:00 PM
#903   I think there are some others playing in savvyj 08/28/15 03:22:29 PM
#902   What is even better is all of this Rookiemove 08/28/15 02:31:54 PM
#901   I think by the way they are holding Rookiemove 08/28/15 01:43:48 PM
#900   This is beautiful! savvyj 08/28/15 12:52:35 PM
#899   SMASH!! Another rip!! GO AVXT $$$$$$ Rookiemove 08/28/15 12:22:45 PM
#898   Bidders just keep on coming!! AVXT STRONG AS A Rookiemove 08/27/15 03:23:34 PM
#897   AVXT chart is squeezed so tight it Rookiemove 08/27/15 02:32:57 PM
#896   MMs piling up.... Rookiemove 08/27/15 12:07:53 PM
#895   Very nice slappage! ! Go AVXT !!! Rookiemove 08/27/15 12:07:07 PM
#894   Here comes the boooom! savvyj 08/27/15 11:55:30 AM
#893   AVAX to relaunch Phase III Trials of MVAX Rookiemove 08/27/15 10:18:09 AM
#892   Quiet Wednesday afternoon in OTC land. AVXT NEEDS TO Rookiemove 08/26/15 03:21:59 PM
#891   The top has been silently picked clean for Rookiemove 08/25/15 03:57:21 PM
#890   When we run its going to be huge! IMO savvyj 08/25/15 03:55:06 PM
#889   .0145 all filled. Could see a run Rookiemove 08/25/15 12:12:25 PM
#888   AVXT would be a nice hedge against a Rookiemove 08/25/15 10:32:58 AM
#887   Held out quite well considering the world Stock johnny canuck 08/24/15 07:59:15 PM
#886   Sorry - made an error johnny canuck 08/22/15 02:59:51 PM
#885   AVXT 400K bidder at 130 EOD Friday. Rookiemove 08/22/15 01:18:14 PM
#884   I believe that the bid is growing AVXT Rookiemove 08/21/15 03:51:51 PM
#883   They are working on financing. They are going johnny canuck 08/20/15 07:45:17 PM
#882   Bio Techs are big in the market, especially Rookiemove 08/20/15 04:38:44 PM
#881   Yep, 180K of ask slaps before the bell, Rookiemove 08/20/15 04:18:13 PM
#880   what are you guys talking about? they need akiaki 08/20/15 04:07:40 PM
#879   Pair of good size buys at end of johnny canuck 08/20/15 04:05:33 PM
#878   I need to be drinking what you are akiaki 08/20/15 04:02:37 PM
#877   Hmmm, interesting. Looking good to me. GO Rookiemove 08/20/15 03:57:46 PM
#876   no bid is growing my friend akiaki 08/20/15 12:34:18 PM
#875   Bid is growing, lots of eyes Rookiemove 08/20/15 11:53:15 AM
#874   From the web site. johnny canuck 08/19/15 08:34:48 PM
#873   Someone asked a few posts back - issued johnny canuck 08/19/15 07:23:22 PM
#872   Financing is very important here, once they are akiaki 08/19/15 06:49:41 PM
#871   Great close today. Very Big things on Rookiemove 08/19/15 04:03:43 PM
#870   Yes it was. Now the trick is johnny canuck 08/19/15 10:32:07 AM
#869   Agreed, website great first step. AVXT $$$$ Rookiemove 08/19/15 10:19:58 AM
#868   I think they need to put out a johnny canuck 08/19/15 07:37:19 AM
#867   Thank's Bayetta. johnny canuck 08/19/15 04:01:12 AM
#866   AVXT Website back up! Data about to bayetta 08/19/15 01:25:20 AM
#865   who is loading? it keeps dropping? they release akiaki 08/18/15 08:23:53 PM
#864   Someone been loading up big time for the Rookiemove 08/18/15 03:40:43 PM
#863   Holding strong. savvyj 08/18/15 03:36:39 PM
#862   I agree! tencoin 08/18/15 01:17:52 PM
#861   An update would be very helpful. Rookiemove 08/18/15 12:10:16 PM
#860   It's only my feel! tencoin 08/18/15 09:09:07 AM
PostSubject